Clinical oncology最新文献

{"title":"Breast Cancer Assessment and Care (BRAC STUDY)","authors":"Josephine Ngugi , Vaishvi Dalal , Shikta Das , Edward Heelas , Charleen Nhova , Steven Al-Hashimi , James Pearson , Neha Chopra , Jajini Varghese","doi":"10.1016/j.clon.2025.104020","DOIUrl":"10.1016/j.clon.2025.104020","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104020"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and outcomes of triple-negative apocrine carcinomas of the breast: A tertiary centre experience over 20 years","authors":"Myrto Kastrisiou , Susanna Slater , Mae Alghawas , Diego Himenez , Stephen Johnston (Professor) , Emma Kipps , Marina Parton , Nicholas Turner (Professor) , Alicia Okines","doi":"10.1016/j.clon.2025.104011","DOIUrl":"10.1016/j.clon.2025.104011","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104011"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid MBP advert AI Conference Journals Ad 19 Feb_01","authors":"","doi":"10.1016/S0936-6555(26)00062-2","DOIUrl":"10.1016/S0936-6555(26)00062-2","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104091"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiotherapy for Oesophageal Adenocarcinoma: The Debate is Not Over","authors":"M. Guardascione , L. Foltran , F. Puglisi","doi":"10.1016/j.clon.2025.103982","DOIUrl":"10.1016/j.clon.2025.103982","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103982"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145908802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparity in Cancer Screening Among Black and Other Ethnic Minority Groups in the UK","authors":"Z. Iyizoba-Ebozue , K. Njoku , A. Fatimilehin , P. Mbanu , S. Adeleke","doi":"10.1016/j.clon.2025.103992","DOIUrl":"10.1016/j.clon.2025.103992","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103992"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility Study Exploring the Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome to Improve the Detection and Management of Gastrointestinal Toxicity","authors":"C.C. Henson ,&nbsp;K. Green ,&nbsp;R. Slater ,&nbsp;J. McLaughlin ,&nbsp;M. Hann ,&nbsp;L. Barraclough ,&nbsp;S. Burden ,&nbsp;L. Gillespie ,&nbsp;T. Ward ,&nbsp;C. Probert","doi":"10.1016/j.clon.2025.103994","DOIUrl":"10.1016/j.clon.2025.103994","url":null,"abstract":"<div><h3><em>Aims</em></h3><div>Eighty percent patients develop gastrointestinal (GI) symptoms during pelvic radiotherapy. The triggering event is a known enabling identification of pathophysiological changes. The focus of this study was feasibility (identification, recruitment, and retention), however, exploratory microbiome and metabolome analyses were performed.</div></div><div><h3><em>Materials and methods</em></h3><div>Patients undergoing pelvic radiotherapy underwent faecal sampling (baseline, week 4, and 6 months), with assessment of GI toxicity using the Imflammatory Bowel Disease Questionnaire (IBDQ) bowel (IBDQB) subset. Participants were split into 2 groups based on IBDQB at week-4. Exploratory analysis was performed to identify differences in metabolome (gas chromatography-mass spectrometry) and microbiome (16s rRNA sequencing).</div></div><div><h3><em>Results</em></h3><div>Two hundred twenty-seven patients were screened, 69 were approached, and 17 were recruited over 18 months (mean age: 61.6 ± 15.3 years; 14 female; 1 withdrawal).</div><div>Metabolome analysis showed lower heptanal and octanal in baseline samples of patients with higher GI toxicity; lower (methyltrisulfanyl)methane in week-4 samples of patients with higher GI toxicity; and higher butanoic acid and benzaldehyde in month 6 samples in patients with higher GI toxicity.</div><div>Whole-group microbiome analysis showed a trend towards decreased alpha diversity at 4 weeks; no differences in beta diversity; and a trend towards increase in <em>Lachnoclostridium</em> and decrease in Ruminococcaceae <em>Incertae sedis</em> at week 4. Microbiome analysis split by GI toxicity showed lower alpha diversity for the high GI toxicity group (each timepoint); no significant difference in beta diversity between groups; more genera differentially abundant between the GI toxicity groups at 4 weeks, than at other timepoints.</div></div><div><h3><em>Conclusion</em></h3><div>Recruitment was lower than anticipated. Attrition was low. Exploratory analysis suggests heptanal and octanal may have a role as a biomarker for GI toxicity, and lower alpha diversity may predict GI toxicity, with <em>Lachnoclostridium</em> and Ruminococcaceae <em>Incertae sedis</em> as bacteria of interest.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103994"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter (CLINONC-2025-990) Regarding Our Study on Functional Outcomes in Extremity Soft Tissue Sarcoma Survivors","authors":"R.G. Hikmet ,&nbsp;L.B.J. Thorsen ,&nbsp;H.K. Rose ,&nbsp;P. Rossen ,&nbsp;T. Baad-Hansen ,&nbsp;T.B. Nyeng ,&nbsp;B.E. Engelmann ,&nbsp;N. Aggerholm-Pedersen","doi":"10.1016/j.clon.2025.103989","DOIUrl":"10.1016/j.clon.2025.103989","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103989"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Numbers to Movement: Making the Toronto Extremity Salvage Score a Living Measure in Soft-tissue Sarcoma Survivorship","authors":"S. Haider","doi":"10.1016/j.clon.2025.104002","DOIUrl":"10.1016/j.clon.2025.104002","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 104002"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to Stereotactic Radiosurgery Centres Across the United Kingdom—An Investigation of Travel Time","authors":"S.D. Robinson ,&nbsp;S. Kingdon ,&nbsp;M. Williams","doi":"10.1016/j.clon.2025.104000","DOIUrl":"10.1016/j.clon.2025.104000","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 104000"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population-Based Outcomes of Single-Fraction Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer","authors":"J.M. Callueng ,&nbsp;S. Baker ,&nbsp;N. Chng ,&nbsp;J.P. Abrina ,&nbsp;D. Hoegler ,&nbsp;D. Petrik ,&nbsp;E.M. Dunne ,&nbsp;I. Mohamed ,&nbsp;R. Halperin ,&nbsp;S. Atrchian ,&nbsp;A. Lin ,&nbsp;A. Ye ,&nbsp;F. Hsu ,&nbsp;D. Schellenberg ,&nbsp;M. Liu ,&nbsp;B. Mou","doi":"10.1016/j.clon.2025.103997","DOIUrl":"10.1016/j.clon.2025.103997","url":null,"abstract":"<div><h3><em>Aims</em></h3><div>Single-fraction stereotactic ablative radiotherapy (SF-SABR) was introduced in British Columbia (BC), Canada, during the COVID-19 pandemic. It persists as a standard treatment owing to its comparable outcomes with fractionated regimens in two randomised phase II trials and advantages in resource utilisation and patient convenience. This study evaluated the clinical outcomes and toxicities in patients treated with SF-SABR for early stage non-small lung cancer (NSCLC) in BC.</div></div><div><h3><em>Materials and methods</em></h3><div>This multi-institution population-based retrospective study included all patients treated with SF-SABR for early stage NSCLC between March 2020 and August 2023 in BC. All lesions were peripheral T1-T2 tumours, less than 5 cm in diameter. All patients were medically inoperable or declined surgery. Prescription doses were either 30 Gy or 34 Gy in one fraction. Assessed clinical outcomes included 2-year local failure (LF), distant failure (DF), and overall survival (OS). Toxicity endpoints were graded according to Common Terminology Criteria for Adverse Events version 5.0.</div></div><div><h3>RESULTS</h3><div>A total of 179 lesions in 166 patients were included. The median follow-up was 23.0 months. The median age was 75 years. The majority (95%) of tumours were T1. The median tumour diameter was 1.5 cm. Prescription doses of 30 Gy and 34 Gy were delivered to 103 (57.5%) and 76 (42.5%) lesions, respectively. The 2-year LF, DF, and OS rates were 7.1%, 14.1%, and 81.5%, respectively. No grade 4 or 5 toxicities were reported. Crude rates of grade 2 and 3 toxicities were 17.3% and 2.2%, respectively. Grade 2 and 3 chest wall toxicity (CWT) rates were 5.6% and 0.6%, respectively. Chest wall abutment, diabetes, and prior thoracic radiation were significant predictors for CWT on univariate analysis.</div></div><div><h3>CONCLUSIONS</h3><div>This multi-institution population-based study demonstrated that SF-SABR for early stage NSCLC had favourable early clinical outcomes and low toxicity rates comparable to data from other SF-SABR and multi-fraction lung SABR studies. Long-term follow-up of outcomes and toxicity for SF-SABR are warranted.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103997"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}